Gracell Biotechnologies (shanghai) Co., Ltd.
Clinical trials sponsored by Gracell Biotechnologies (shanghai) Co., Ltd., explained in plain language.
-
New Dual-Target CAR t therapy shows promise for Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called GC012F for people with multiple myeloma, a type of blood cancer, that has returned or stopped responding to at least three prior treatments. GC012F uses a patient's own immune cells, modified to target two proteins (CD19 and BCMA) on cancer…
Phase: PHASE1, PHASE2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New CAR t therapy targets Hard-to-Treat AL amyloidosis
Disease control Recruiting nowThis early-phase trial tests a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to prior therapy. The therapy uses a patient's own immune cells, modified to target two proteins on harmful cells. The main goals are to check safety and …
Phase: PHASE1 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Lupus breakthrough? new injection targets immune cells
Disease control Recruiting nowThis study tests an injection called GC012F in 118 adults with refractory systemic lupus erythematosus (lupus that hasn't responded to standard treatments). The therapy aims to control the disease by targeting certain immune cells. Researchers will check safety and how well it re…
Phase: PHASE1, PHASE2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC